Hansa Medical's Nomination Committee for the AGM 2018 appointed

17 Nov 2017, 08:00

Regulatory information

In accordance with the decision of the Annual General Meeting on May 23, 2017, a Nomination Committee for the Hansa Medical AGM 2018 has been formed. Based on the list of shareholders as of 31 August 2017, the three largest shareholders have been contacted and invited to each appoint a representative to the Nomination Committee. The Nomination Committee consists of Erika KjellbergEriksson representing Nexttobe AB, Max Mitteregger representing Gladiator and Sven Sandberg representing Thomas Olausson. The Nomination Committee also includes the chairman of the board, Birgit Stattin Norinder, as convener. Furthermore, the company publishes financial calendar for 2018.

The function of the Nomination Committee is to prepare and submit proposals for the AGM regarding the number of board members to be elected by the general meeting, election of chairman and other board members, board fees and any remuneration for committee work, election of chairman of the Annual General Meeting, election of auditors (if applicable) and the auditors and proposals for rules for the Nominating Committee for the AGM in 2018.

The Annual General Meeting of Hansa Medical AB (publ) will be held May 29, 2018 in the Auditorium (Hörsalen) by the company's premises at Scheelevägen 22 in Lund.

Shareholders wishing to submit comments or submit proposals to the Nomination Committee may do so no later than 29 March 2018 via email to info@hansamedical.com or by letter to Hansa Medical, Nomination Committee, Box 785, 220 07 Lund, Sweden.

The Nomination Committee's proposals will be presented in the notice convening the AGM and on the company's website.

Financial calendar
Year-end report 2017                                        14 February 2018
Annual report 2017                                            11 April 2018
Interim report for January – March 2018           25 April 2018
Annual General Meeting                                    29 May 2018
Interim report for January – June 2018             19 July 2018
Interim report for January – September 2018   1 November 2018

This information is such information that Hansa Medical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:00 am CET on 17 November 2017.

Files

Hansa Medical's Nomination Committee for the AGM 2018 appointed

For further information, please contact:
Emanuel Björne, Vice President Business Development and Investor Relations, Hansa Medical AB (publ)
Mobile: 46707175477
E-mail: emanuel.bjorne@hansamedical.com

About Hansa Medical AB
Hansa Medical is a biopharmaceutical company developing novel immunomodulatory enzymes for transplantation and acute autoimmune diseases. The lead product, IdeS, is a proprietary antibody-degrading enzyme currently in late- stage clinical development for kidney transplant patients, with significant potential for further development in other solid organ transplants and in acute autoimmune indications. The company also has a strong pipeline of preclinical projects that may provide a second wave of potential drugs. Under the project name NiceR, novel immunoglobulin cleaving enzymes are developed for repeat dosing with the objective of treating relapsing autoimmune diseases and cancer. Hansa Medical is based in Lund, Sweden, its shares (ticker: HMED) are listed on Nasdaq Stockholm.